Serum osteoprotegerin level in children with nephrotic syndrome and the effect of glucocorticoid on it

LI Yu-Liu; WANG Hua

PDF(951 KB)

Chinese Journal of Contemporary Pediatrics ›› 2012, Vol. 14 ›› Issue (09) : 653-656.

CLINICAL RESEARCH

Serum osteoprotegerin level in children with nephrotic syndrome and the effect of glucocorticoid on it

LI Yu-Liu, WANG Hua

Author information +

History +

Abstract

OBJECTIVE: To observe serum osteoprotegerin (OPG) level in children with nephrotic syndrome (NS) and changes in serum OPG level after glucocorticoid therapy, with the aim of studying the role of OPG in the bone metabolism of children with NS. METHODS: Forty-four children with idiopathic NS were randomly selected as the study group, including 24 newly diagnosed, untreated patients and 20 who had relapsed during the process of glucocorticoid reduction (cumulative dose of glucocorticoid 28327±5879 mg/m2). Twenty-three age- and sex-matched healthy children served as the control group.Serum osteoprotegerin (OPG) level was measured using ELISA. Serum N-terminal midfragment of osteocalcin (N-MID osteocalcin) was determined using electrochemical luminescence immunoassays (ECLIA). RESULTS: Serum levels of OPG (211±55 ng/L) and N-MID osteocalcin (46±14 ng/mL) in the untreated NS group were reduced compared with 470±57 ng/L (OPG) and 73±9 ng/ml (N-MID osteocalcin) in the control group (P<0.05). Serum levels of OPG (176±42 ng/L) and N-MID osteocalcin (29±10 ng/mL) in the NS relapsed group were lower than in the untreated NS and control groups (P<0.05). CONCLUSIONS: Bone metabolism disorders are found in children with NS. High-doses of glucocorticoid therapy can aggravate these disorders. Serum OPG levels in children with NS may be affected by both the renal disease itself and steroid therapy, suggesting that OPG is expected to become a new biochemical indicator for predicting changes to the bone metabolism of children with NS.

Key words

Nephritic syndrome / Glucocorticoid / Osteoprotegerin / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Yu-Liu, WANG Hua. Serum osteoprotegerin level in children with nephrotic syndrome and the effect of glucocorticoid on it[J]. Chinese Journal of Contemporary Pediatrics. 2012, 14(09): 653-656

References

［1］胡亚美，江载芳.诸福棠实用儿科学［M］.第7版.北京：人民卫生出版社，2002：1641-1644.

［2］廖祥鹏，颜崇淮，刘忠厚，张伟利.骨质疏松症的预防应该重视孕妇和儿童的骨骼健康［J ］.中国骨质疏松杂志，2009，15（4）:299-303.

［3］Simonet WS, Lacey DL, Cunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotege: a novel secreted protein involved in the regulation of bone density ［J］. Cell, 1997, 89(2): 309-319.

［4］Yasuda H. Bone and bone related biochemical examinations. Bone and collagen related metabolites. Receptor activator of NF-kappaB ligand(RANKL)［J］. Clin Calcium, 2006 16(6): 964-970.

［5］梁青春，徐康，刘江华，盛志峰，廖二元.OPG基因敲除小鼠骨量及微结构的改变［J］. 中国现代医学杂志，2011，21（17）:1989-1994.

［6］Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis［J］. Bone, 2002, 30(6): 853-858.

［7］唐述森，王文君，范林艳，代瑞珍，刘焕彩，糖皮质激素对ITP患者骨代谢的影响及机制［J］.山东医药，2010,50(39):89-90.

［8］江莎，侯加法.骨钙素临床应用研究进展［J］.中国骨质疏松杂志，2010, 16(5):360-364.

［9］Delmas PD, Christiansen C, Mann KG, Price PA, Bone gla protein (osteocalcin) assay standradization report［J］. J Bone Miner Res, 1990, 5(1): 5-11.

［10］Sierra RI, Specker BL, Jiménez F, Cruz C, Pedraza-Chaverrí J. Biochemical bone markers, bone mineral content, and bone mineral density in rats with experimental nephrotic syndrome［J］. Ren Fail, 1997, 19(3): 409-424.

［11］Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis［J］. Endocrinology, 1999, 140(10): 4382-4389.

［12］Vidal NO, Br-ndstrom H, Jonsson KB, Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids［J］. J Endocrinol, 1998, 159(1): 191-195.

［13］王建忠，王坤正，时志斌，张明宇.激素性股骨头坏死患者股骨头骨组织骨保护素NF-κB受体活化因子配基mRNA表达［J］.中国修复重建外科杂志，2008, 22(10): 1161-1164

［14］杨海英，董俊华，孔春研，王进.糖皮质激素对肾病综合征患儿成骨细胞功能的影响［J］. 中国当代儿科杂志，2005,7(2)：141-146.

［15］骆培良，江芸.糖皮质激素对肾病综合征患儿生长激素-胰岛素样生长因子轴的影响［J］. 实用医学杂志，2009,25(24)：4170-4171.